Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $235
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $210 to $235.
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $210 to $235.